Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China.
Clin Infect Dis. 2020 Jul 28;71(15):793-798. doi: 10.1093/cid/ciaa345.
Coronavirus disease 2019 (COVID-19) has become a public health emergency. The widely used reverse transcription-polymerase chain reaction (RT-PCR) method has limitations for clinical diagnosis and treatment.
A total of 323 samples from 76 COVID-19-confirmed patients were analyzed by droplet digital PCR (ddPCR) and RT-PCR based 2 target genes (ORF1ab and N). Nasal swabs, throat swabs, sputum, blood, and urine were collected. Clinical and imaging data were obtained for clinical staging.
In 95 samples that tested positive by both methods, the cycle threshold (Ct) of RT-PCR was highly correlated with the copy number of ddPCR (ORF1ab gene, R2 = 0.83; N gene, R2 = 0.87). Four (4/161) negative and 41 (41/67) single-gene positive samples tested by RT-PCR were positive according to ddPCR with viral loads ranging from 11.1 to 123.2 copies/test. The viral load of respiratory samples was then compared and the average viral load in sputum (17 429 ± 6920 copies/test) was found to be significantly higher than in throat swabs (2552 ± 1965 copies/test, P < .001) and nasal swabs (651 ± 501 copies/test, P < .001). Furthermore, the viral loads in the early and progressive stages were significantly higher than that in the recovery stage (46 800 ± 17 272 vs 1252 ± 1027, P < .001) analyzed by sputum samples.
Quantitative monitoring of viral load in lower respiratory tract samples helps to evaluate disease progression, especially in cases of low viral load.
2019 年冠状病毒病(COVID-19)已成为公共卫生紧急事件。广泛使用的逆转录-聚合酶链反应(RT-PCR)方法在临床诊断和治疗方面存在局限性。
对 76 例 COVID-19 确诊患者的 323 份样本进行了基于 2 个靶基因(ORF1ab 和 N)的液滴数字 PCR(ddPCR)和 RT-PCR 分析。采集鼻拭子、咽拭子、痰、血和尿样本。根据临床和影像学数据对临床分期进行了分析。
在两种方法均为阳性的 95 份样本中,RT-PCR 的循环阈值(Ct)与 ddPCR 的拷贝数高度相关(ORF1ab 基因,R2=0.83;N 基因,R2=0.87)。根据 ddPCR,4 份(161 份中的 4 份)经 RT-PCR 检测为阴性和 41 份(67 份中的 41 份)单基因阳性样本呈阳性,病毒载量范围为 11.1 至 123.2 拷贝/测试。然后比较了呼吸道样本的病毒载量,发现痰中病毒载量(17429±6920 拷贝/测试)明显高于咽拭子(2552±1965 拷贝/测试,P<.001)和鼻拭子(651±501 拷贝/测试,P<.001)。此外,痰样本中早期和进展期的病毒载量明显高于恢复期(46800±17272 与 1252±1027,P<.001)。
定量监测下呼吸道样本中的病毒载量有助于评估疾病进展,特别是在病毒载量较低的情况下。